Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
May 14, 2020Targovax announces that the ONCOS-102 and durvalumab abstract is selected for a Poster Discussion Session at ASCO
-
May 7, 2020Targovax ASA: First quarter 2020 results
-
May 6, 2020Targovax announces that abstract on interim phase I clinical data from the phase I/II peritoneal trial is accepted at ASCO
-
May 5, 2020Targovax ASA issues options to new member of management
First quarter 2020
Targovax ASA (OSE: TRVX) announced its first quarter 2020 results on Thursday 7 May 2020.